دورية أكاديمية
[Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model].
| العنوان: | [Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model]. |
|---|---|
| عنوان ترانسليتريتد: | Molekuliarnye mekhanizmy gipolipidemicheskogo deĭstviia tsitoprotektora kramizola pri éksperimental'noĭ dislipidemii. |
| المؤلفون: | Lizunov AV; Institute of Experimental Medicine, St. Petersburg, Russia; St Petersburg University, St. Petersburg, Russia., Okunevich IV; Institute of Experimental Medicine, St. Petersburg, Russia., Lebedev AA; Institute of Experimental Medicine, St. Petersburg, Russia., Bychkov ER; Institute of Experimental Medicine, St. Petersburg, Russia; Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, St. Petersburg, Russia., Piotrovskiy LB; Institute of Experimental Medicine, St. Petersburg, Russia., Shabanov PD; Institute of Experimental Medicine, St. Petersburg, Russia; Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, St. Petersburg, Russia. |
| المصدر: | Biomeditsinskaia khimiia [Biomed Khim] 2020 Jul; Vol. 66 (4), pp. 326-331. |
| نوع المنشور: | Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: Rossiĭskai︠a︡ akademii︠a︡ medit︠s︡inskikh nauk Country of Publication: Russia (Federation) NLM ID: 101196966 Publication Model: Print Cited Medium: Print ISSN: 2310-6972 (Print) Linking ISSN: 23106905 NLM ISO Abbreviation: Biomed Khim Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Moskva : Rossiĭskai︠a︡ akademii︠a︡ medit︠s︡inskikh nauk, 2003- |
| مواضيع طبية MeSH: | Dyslipidemias*/drug therapy , Dyslipidemias*/genetics , Fenofibrate* , Hyperlipidemias*/drug therapy, Animals ; Cholesterol, HDL ; Hypolipidemic Agents/pharmacology ; Hypolipidemic Agents/therapeutic use ; Rats ; Triglycerides/metabolism |
| مستخلص: | The tested drug cramizol exhibits lipid-lowering and anti-atherogenic effects. Cramizol reduces blood cholesterol and triglycerides. It also increases HDL and reduces the atherogenic index in rats with the chronic dyslipidemia model induced by a hypercholesterol diet. Cramizol is effective as a hypolipidemic agent and its efficiency is comparable with the reference drug, phenofibrate. Cramizol increases expression of the ApoA1 and ApoC2 genes, and also reduces expression of the Scarb1 gene in rats with experimentally induced hyperlipidemia. These mechanisms could be the basis of its hypolipidemic and anti-atherogenic actions. |
| فهرسة مساهمة: | Keywords: SR-B1; alimentary model; apolipoprotein A1; apolipoprotein C2; cholesterol; cramizol; experimental chronic dyslipidemia; triglycerides Local Abstract: [Publisher, Russian] Sinteticheskiĭ preparat kramizol (proizvodnoe imidazol-dikarbonovoĭ kisloty) obladaet gipolipidemicheskim i antiaterogennym deĭstviem. Na modeli alimentarnoĭ dislipidemii (DLP), vyzvannoĭ u krys ratsionom s izbytkom pishchevogo kholesterina i smesi zhirov, preparat kramizol snizhaet soderzhanie obshchego kholesterina i triglitseridov v krovi, povyshaet soderzhanie lipoproteinov vysokoĭ plotnosti v krovi, a takzhe znachitel'no umen'shaet velichinu raschetnogo kholesterinovogo koéffitsienta aterogennosti. Po vyrazhennosti gipolipidemicheskogo deĭstviia kramizol sravnim s étalonnym gipolipidemicheskim preparatom fenofibratom. Kramizol uvelichivaet uroven' ékspressii genov ApoA1 i ApoC2, a takzhe snizhaet uroven' ékspressii gena Scarb1 v pecheni u krys s éksperimental'no indutsirovannoĭ alimentarnoĭ DLP. Éti mekhanizmy, vozmozhno, iavliaiutsia osnovoĭ ego gipolipidemicheskogo deĭstviia. |
| المشرفين على المادة: | 0 (Cholesterol, HDL) 0 (Hypolipidemic Agents) 0 (Triglycerides) U202363UOS (Fenofibrate) |
| تواريخ الأحداث: | Date Created: 20200907 Date Completed: 20201030 Latest Revision: 20201030 |
| رمز التحديث: | 20221213 |
| DOI: | 10.18097/PBMC20206604326 |
| PMID: | 32893822 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2310-6972 |
|---|---|
| DOI: | 10.18097/PBMC20206604326 |